After The Cliff: Fewer Patent Expiries Mean Less Savings From Generics

A PwC report on medical cost trends projects that while US health care cost-growth has plateaued, several inflationary factors remain, including a reduction in big-ticket prescription drugs going off-patent. The trend began in 2016 and is expected to continue in 2018.

Cliffs-Saudia-Arabia_562044328_1200

The trend of diminishing health care cost-saving opportunities from newly available generic drugs is expected to continue in 2018, furthering a headwind that began in 2016, a new report from PwC Health Research Institute notes.

The significant patent cliff that was experienced by the industry five years ago – when big blockbuster drugs lost patent...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip